Skip to main content

Table 3 Oncotype DX, Prosigna, and Ellen performance

From: The effects of lymph node status on predicting outcome in ER+ /HER2- tamoxifen treated breast cancer patients using gene signatures

 

LN- Patients

LN+ Patients

 

p value

Concordance

p value

Concordance

Oncotype DX

1.26E-04

0.78

3.06E-01

0.58

Prosigna

8.07E-04

0.79

1.34E-02

0.62

Ellen

1.27E-06

0.85

1.74E-04

0.71

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us